Drugs in Dev. Dermatology
Phase I
Japan 
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
Details : The partnership aims to focus on the clinical development of TRK-820 (nalfurafine hydrochloride), which is being evaluated for the treatment of Uremic Pruritus.
Product Name : TRK-820
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ME3183
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ME3183 is an orally-available and selective inhibitor for phosphodiesterase 4 (PDE4) discovered by Meiji. In the study, ME3183 has been shown to be safe and well-tolerated across the doses tested.
Product Name : ME3183
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2021
Lead Product(s) : ME3183
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
